Literature DB >> 19191851

Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective.

Prateek Sharma1, William Chey, Richard Hunt, Loren Laine, Peter Malfertheiner, Sachin Wani.   

Abstract

Gastroesophageal reflux disease (GERD) is an extremely common chronic disorder associated with impaired quality of life and huge economic burden. Recently, an International Consensus Group developed a global definition of GERD (The Montreal Definition): a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The traditional endoscopy-based classification of GERD patients into one of three groups - non-erosive reflux disease, erosive esophagitis, and Barrett's esophagus - is fraught with several limitations. Due to the lack of a gold standard, GERD is a symptom-based diagnosis, and hence symptom evaluation will remain the primary means by which treatment decisions are made for patients with suspected GERD. We propose that patients reporting the predominant GERD-like symptoms (GERS) in the primary care setting be classified based upon their response to an empiric trial of acid suppressive therapy: complete response to acid suppressive therapy, partial response to acid suppressive therapy, and no response to acid suppressive therapy. Given the limitations of objective medical testing, implementation of our proposed new symptom-based classification of patients with GERS would guide primary care physicians on when to refer patients to a gastroenterologist, which in turn could help in better resource utilization. Validation of this proposed classification by well-designed prospective multicenter studies is awaited.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191851     DOI: 10.1111/j.1442-2050.2008.00934.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  1 in total

1.  Patient or physician - who is able to evaluate gastroesophageal reflux disease symptoms better?

Authors:  Anita Gasiorowska
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.